Gradient Health’s Post

𝐴 𝑛𝑒𝑤 𝑏𝑟𝑎𝑖𝑛 ℎ𝑜𝑟𝑚𝑜𝑛𝑒 ℎ𝑎𝑠 𝑗𝑢𝑠𝑡 𝑏𝑒𝑒𝑛 𝑑𝑖𝑠𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑖𝑛 𝑎𝑛𝑖𝑚𝑎𝑙𝑠. 𝐼𝑡 𝑐𝑜𝑢𝑙𝑑 ℎ𝑎𝑣𝑒 𝑎𝑝𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠 𝑖𝑛 𝑣𝑎𝑟𝑖𝑜𝑢𝑠 𝑝𝑎𝑡ℎ𝑜𝑙𝑜𝑔𝑖𝑒𝑠 𝑟𝑒𝑞𝑢𝑖𝑟𝑖𝑛𝑔 𝑏𝑜𝑛𝑒 𝑠𝑜𝑙𝑖𝑑𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛. 𝐹𝑜𝑐𝑢𝑠 𝑜𝑛 𝑚𝑎𝑡𝑒𝑟𝑛𝑎𝑙 𝑏𝑟𝑎𝑖𝑛 ℎ𝑜𝑟𝑚𝑜𝑛𝑒 ... 🦴 Osteoporosis affects around 200 million people worldwide. This medical condition is characterized by 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞𝐝 𝐛𝐨𝐧𝐞 𝐟𝐫𝐚𝐠𝐢𝐥𝐢𝐭𝐲, which can lead to fractures. It is particularly prevalent in women during the 𝐦𝐞𝐧𝐨𝐩𝐚𝐮𝐬𝐞, as estrogen production declines. This hormone is 𝐞𝐬𝐬𝐞𝐧𝐭𝐢𝐚𝐥 𝐟𝐨𝐫 𝐛𝐨𝐧𝐞 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧. However, its production also declines during breastfeeding, without increasing the risk of fractures. This was precisely the question that interested a team from San Diego. 🦴 These researchers recently published in 𝑁𝑎𝑡𝑢𝑟𝑒 the discovery of 𝐦𝐚𝐭𝐞𝐫𝐧𝐚𝐥 𝐛𝐫𝐚𝐢𝐧 𝐡𝐨𝐫𝐦𝐨𝐧𝐞 (CCN3) in animals. Their study showed that this hormone 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞𝐬 𝐛𝐨𝐧𝐞 𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐛𝐲 𝐬𝐭𝐢𝐦𝐮𝐥𝐚𝐭𝐢𝐧𝐠 𝐛𝐨𝐧𝐞 𝐬𝐭𝐞𝐦 𝐜𝐞𝐥𝐥𝐬, in both young and old individuals. The researchers also investigated how CCN3 supplementation could be administered using a 𝐡𝐲𝐝𝐫𝐨𝐠𝐞𝐥 𝐩𝐚𝐭𝐜𝐡, with direct administration to a fracture, for example. The results in senior mice were promising. 🦴 Beyond osteoporosis, several populations and medical conditions may present an increased risk of fractures, such as women with 𝐛𝐫𝐞𝐚𝐬𝐭 𝐜𝐚𝐧𝐜𝐞𝐫 treated with hormone therapy, and 𝐲𝐨𝐮𝐧𝐠 𝐞𝐥𝐢𝐭𝐞 𝐚𝐭𝐡𝐥𝐞𝐭𝐞𝐬. #osteoporosis #hormone #ostéoporose #research #recherche #santé #health #medicine #médecine

Practice Point 2.2.5 underscores the importance of utilizing disease-specific, externally validated prediction equations in individuals with immunoglobulin A nephropathy (IgAN) and autosomal dominant polycystic kidney disease (ADPKD). For ADPKD, two reliable prediction tools, the Mayo Clinic Classification tool and the Predicting Renal Outcome in Polycystic Kidney Disease (PROPKD) score, offer insights into long-term kidney failure risk and inform therapy decisions, particularly regarding tolvaptan use. These tools have demonstrated accuracy and effectiveness in external validation. In the case of IgAN, two externally validated prediction models, one clinical and the other incorporating histological factors (MEST score), offer enhanced accuracy, particularly when including histological data. These models provide valuable guidance for clinical decision-making, with improved accuracy in identifying high-risk individuals. Given the availability of precise and validated models, it is recommended to prioritize their use over more generalized CKD models in individuals with diagnosed IgAN or ADPKD. However, it's essential to recognize that IgAN can manifest as rapidly progressive disease, which may not always be fully represented in existing prediction tools. Link to the 2024 KDIGO Guidelines: https://lnkd.in/gDVT83EE #KDIGO2024 #ClinicalPracticeGuideline #ESRD #CKD #ESKD #Kidneydisease #RenalFailure #RenalReplacment #dialysis #hemodialysis #ChronicKidneyDisease #IgAN #ADPKD #RiskPrediction #PrecisionMedicine #HealthcareInnovation #DiseaseManagement #Nephrology #MedicalResearch #PatientCare #PersonalizedMedicine

𝐴 𝑛𝑒𝑤 𝑏𝑟𝑎𝑖𝑛 ℎ𝑜𝑟𝑚𝑜𝑛𝑒 ℎ𝑎𝑠 𝑗𝑢𝑠𝑡 𝑏𝑒𝑒𝑛 𝑑𝑖𝑠𝑐𝑜𝑣𝑒𝑟𝑒𝑑 𝑖𝑛 𝑎𝑛𝑖𝑚𝑎𝑙𝑠. 𝐼𝑡 𝑐𝑜𝑢𝑙𝑑 ℎ𝑎𝑣𝑒 𝑎𝑝𝑝𝑙𝑖𝑐𝑎𝑡𝑖𝑜𝑛𝑠 𝑖𝑛 𝑣𝑎𝑟𝑖𝑜𝑢𝑠 𝑝𝑎𝑡ℎ𝑜𝑙𝑜𝑔𝑖𝑒𝑠 𝑟𝑒𝑞𝑢𝑖𝑟𝑖𝑛𝑔 𝑏𝑜𝑛𝑒 𝑠𝑜𝑙𝑖𝑑𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛. 𝐹𝑜𝑐𝑢𝑠 𝑜𝑛 𝑚𝑎𝑡𝑒𝑟𝑛𝑎𝑙 𝑏𝑟𝑎𝑖𝑛 ℎ𝑜𝑟𝑚𝑜𝑛𝑒 ... 🦴 Osteoporosis affects around 200 million people worldwide. This medical condition is characterized by 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞𝐝 𝐛𝐨𝐧𝐞 𝐟𝐫𝐚𝐠𝐢𝐥𝐢𝐭𝐲, which can lead to fractures. It is particularly prevalent in women during the 𝐦𝐞𝐧𝐨𝐩𝐚𝐮𝐬𝐞, as estrogen production declines. This hormone is 𝐞𝐬𝐬𝐞𝐧𝐭𝐢𝐚𝐥 𝐟𝐨𝐫 𝐛𝐨𝐧𝐞 𝐩𝐫𝐨𝐝𝐮𝐜𝐭𝐢𝐨𝐧. However, its production also declines during breastfeeding, without increasing the risk of fractures. This was precisely the question that interested a team from San Diego. 🦴 These researchers recently published in 𝑁𝑎𝑡𝑢𝑟𝑒 the discovery of 𝐦𝐚𝐭𝐞𝐫𝐧𝐚𝐥 𝐛𝐫𝐚𝐢𝐧 𝐡𝐨𝐫𝐦𝐨𝐧𝐞 (CCN3) in animals. Their study showed that this hormone 𝐢𝐧𝐜𝐫𝐞𝐚𝐬𝐞𝐬 𝐛𝐨𝐧𝐞 𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐛𝐲 𝐬𝐭𝐢𝐦𝐮𝐥𝐚𝐭𝐢𝐧𝐠 𝐛𝐨𝐧𝐞 𝐬𝐭𝐞𝐦 𝐜𝐞𝐥𝐥𝐬, in both young and old individuals. The researchers also investigated how CCN3 supplementation could be administered using a 𝐡𝐲𝐝𝐫𝐨𝐠𝐞𝐥 𝐩𝐚𝐭𝐜𝐡, with direct administration to a fracture, for example. The results in senior mice were promising. 🦴 Beyond osteoporosis, several populations and medical conditions may present an increased risk of fractures, such as women with 𝐛𝐫𝐞𝐚𝐬𝐭 𝐜𝐚𝐧𝐜𝐞𝐫 treated with hormone therapy, and 𝐲𝐨𝐮𝐧𝐠 𝐞𝐥𝐢𝐭𝐞 𝐚𝐭𝐡𝐥𝐞𝐭𝐞𝐬. #osteoporosis #hormone #ostéoporose #research #recherche #santé #health #medicine #médecine

Increased Risk of Benign Prostate Hyperplasia (BPH) in Patients with Gout: A Longitudinal Follow-Up Study Using a National Health Screening Cohort Benign prostatic hyperplasia (#bph ) is histologically defined as the abnormal proliferation of epithelial and stromal cells in the #prostate gland, which encompasses the proximal urethra [1]. Approximately 26.2% of the population is estimated to suffer from BPH [2]. The prevalence of BPH increases with age, as more than 50% of the population older than 60 years has BPH [3]. In Korea, approximately 20.0% of males are diagnosed with BPH, and the prevalence of BPH is as high as 26.6% in populations older than 70 years [4]. To relieve the difficulties in emptying and retaining patients, several types of medical and surgical approaches are employed [5,6,7]. Because many of these treatments cannot reverse the changes in prostate hyperplasia, preventive management and the delineation of the risk factors of BPH are important. A number of lifestyle factors, such as #obesity ; high intake of #carbohydrates , fat, protein, and #sugar ; #smoking ; #alcohol consumption; and sedentary behavior, have been suggested to increase the risk of BPH [8]. In addition, comorbidities, including metabolic disorders such as #diabetes and related medications, #hypertension , and dyslipidemia, are purportedly associated with increased susceptibility to BPH [9]. #gout is one of the most common #inflammatory #arthritis types. Uric acid deposits mainly originate from chronic #hyperuricemia, which causes inflammatory arthritis [10]. Because gout also involves the perturbation of metabolism, which results in the deposition of urate crystals and inflammation, patients with gout may be more vulnerable to the development of BPH. Indeed, a previous cohort study reported a 1.3 times greater risk of BPH in patients with gout [12]. In particular, a young male population aged >60 years demonstrated a high risk of BPH among gout patients but not in a population older than 60 years. Moreover, an association between uric acid levels and the risk of BPH has been suggested. A population cohort study reported a lower risk of BPH related to urate-lowering medication, such as allopurinol [13]. #Allopurinol use lowers the risk of BPH in terms of medication, diagnosis, and surgery (HR = 0.81 [0.75–0.88], 0.78 [0.71–0.86], and 0.67 [0.58–0.76]) [13]. #menshealth #nutrition #keto #microbiome #nih #publichealth https://lnkd.in/eaHjhseG

How is biotech pioneering new patient options for endometriosis? 🚀 Affecting around 190 million women and girls, endometriosis is a condition that has been rather difficult to treat with no cures to date. 📅 It is caused by the growth of tissue outside the uterus, leading to debilitating pelvic pain during sex and heavy periods. With some clinical trials showing promise and with the discovery of new drug targets, there is hope for better endometriosis care. 💊 Read our latest article to find out about some of the recent advancements in endometriosis research! 👇 https://lnkd.in/dXAXCu7w #endometriosis #biotechinnovation #womenshealth #clinicaltrials #medicalresearch #healthcareinnovation #biotechnews Bruce Nicholson | Hera Biotech | The University of Edinburgh | TiumBio | Serac Healthcare | Western Sydney University | FimmCyte | Celmatix

𝐒𝐞𝐞𝐢𝐧𝐠 𝐁𝐞𝐲𝐨𝐧𝐝 𝐭𝐡𝐞 𝐒𝐮𝐫𝐟𝐚𝐜𝐞: 𝐇𝐢𝐬𝐭𝐨𝐩𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐲'𝐬 𝐈𝐦𝐩𝐚𝐜𝐭 𝐨𝐧 𝐎𝐜𝐮𝐥𝐚𝐫 𝐁𝐫𝐞𝐚𝐤𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐬 🧫👀 In the battle against ocular diseases, the victories are often silent but profound. Histopathology has been the silent partner in these successes, offering insights that transform patient outcomes. 👁️ 𝐂𝐚𝐬𝐞 𝐢𝐧 𝐏𝐨𝐢𝐧𝐭: 𝐀𝐠𝐞-𝐫𝐞𝐥𝐚𝐭𝐞𝐝 𝐌𝐚𝐜𝐮𝐥𝐚𝐫 𝐃𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐢𝐨𝐧 (𝐀𝐌𝐃): When treatments for AMD were in their infancy, histopathology provided the map that guided scientists to understand the choroidal neovascularization process, leading to anti-VEGF therapies that now preserve vision for millions. 𝐃𝐢𝐚𝐛𝐞𝐭𝐢𝐜 𝐑𝐞𝐭𝐢𝐧𝐨𝐩𝐚𝐭𝐡𝐲: As the prevalence of diabetes soared, so did this sight-threatening complication. Histopathological analysis identified the microvascular damage caused by hyperglycemia, paving the way for targeted treatments and preventive strategies now in clinical use. 𝐆𝐥𝐚𝐮𝐜𝐨𝐦𝐚: This silent thief of sight was once untamable. Histopathological studies of trabecular meshwork and optic nerve damage have been crucial in the development of drugs that better manage intraocular pressure and protect against nerve damage. 🔍 Behind each of these stories is #StageBio. Our commitment to excellence in histopathology has helped usher in a new era of therapies that not only treat but also aim to prevent the progression of devastating ocular diseases. If you're striving to make the next leap in ocular therapy, connect with us. Let's discuss how StageBio's expertise can elevate your research from promising to groundbreaking 🤝. #histopathology #ocularpathology #AMDTreatment #diabeticretinopathy #glaucoma #researchexcellence

𝐅𝐢𝐫𝐬𝐭 𝐀𝐦𝐧𝐢𝐨𝐭𝐢𝐜 𝐅𝐥𝐮𝐢𝐝-𝐃𝐞𝐫𝐢𝐯𝐞𝐝 𝐇𝐮𝐦𝐚𝐧 𝐎𝐫𝐠𝐚𝐧𝐨𝐢𝐝𝐬 𝐖𝐢𝐥𝐥 𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐏𝐫𝐞𝐧𝐚𝐭𝐚𝐥 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐈𝐧 𝐀 𝐍𝐞𝐰 𝐄𝐫𝐚. #Researchers created 3D models of developing organs from #fetal cells, which are present in amniotic fluid, to help #prenatal diagnosis and speed up innovative therapeutic strategies in rare diseases. #Congenital disorders, according to WHO (World Health Organization), affect 6% of newborns globally, causing significant illness and death and therefore representing a major health burden, especially in low- and middle-income countries with limited treatment options. These prenatal anomalies, also known as birth defects, develop prenatally during intra-uterine life and may be identified at birth, or later on. The full article is available in the link below and it is written by By Roberto Oleari, Department of Pharmacological and Biomolecular Sciences “Rodolfo Paoletti”, University of Milan https://lnkd.in/dFPwxR9j #PrenatalPrecisionMedicine #biotech #Congenitaldisorders #lifescience  #therapy  #innovation  #ITTBioMed

Metformin is one of the simple (structurally) and elegant drugs that exerts specificity and yet hits multiple targets resulting in better glucose utilization in many intrinsic ways with minimal adverse effects. About 150 million people are on Metformin, as it is probably the most gentle drug among anti-diabetic medications  with a multimodal and eu-metabolic mechanism of action which are very specific in their activity and avoid  the severe side effects such as hypoglycemia and hyperinsulinemia. The other popular antidiabetic medications such as sulfonylureas and SGLT inhibitors have the side effects mentioned above and even UTIs due to  localized high glucose accumulation. One of the noteworthy aspects of the mechanisms of action of this drug is promoting the secretion of incretin which causes appetite suppression leading to weight loss. There have been past studies on the anti-aging effects of Metformin, but this recent work seems very thorough having been conducted in a species closer to humans. This study applies multimodal analysis, establishing the robustness and near conclusive proof of the metformin anti-aging hypothesis. https://lnkd.in/ew8rTThU National Institute on Aging (NIA) Ageing and Neurodegenerative Diseases Journal Milken Institute Future of Aging Ageing and Neurodegenerative Diseases Journal UNSW Centre for Healthy Brain Ageing (CHeBA) Cologne Graduate School of Ageing Research

Pretty interesting innovative announcement from Roche Diagnostics, which has received approval for a new way to diagnose Polycystic Ovary Syndrome (PCOS) PCOS. PCOS is a common condition in women that can affect their reproductive system, metabolism, and mental well-being. The new method involves a blood test called Elecsys Anti-Müllerian Hormone (AMH) which is a huge development because it provides a quicker, easier way to diagnose PCOS for women with less discomfort. Previous methods, like transvaginal ultrasounds, can be uncomfortable. This is significantly different than the in vitro diagnostic test offered by Roche which is helping to change the landscape to provide further equity and access for the women's health landscape. https://lnkd.in/dNawPKbM

𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐞𝐬 𝐀𝐪𝐧𝐞𝐮𝐫𝐬𝐚 𝐟𝐨𝐫 𝐍𝐢𝐞𝐦𝐚𝐧𝐧-𝐏𝐢𝐜𝐤 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐓𝐲𝐩𝐞 𝐂 📢 The U.S. FDA has approved Aqneursa (levacetylleucine) for treating neurological symptoms associated with Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing at least 15 kg. This marks the second approval for NPC in just one week, highlighting the FDA's commitment to advancing treatments for rare diseases. NPC is a rare genetic disorder leading to progressive neurological symptoms and organ dysfunction, typically resulting in a life expectancy of about 13 years. The approval was based on a 24-week randomized, double-blind, placebo-controlled study involving 60 patients, demonstrating improved outcomes in the modified Scale for the Assessment and Rating of Ataxia (fSARA). Common side effects include abdominal pain, difficulty swallowing, upper respiratory infections, and vomiting. Aqneursa should be taken orally up to three times daily, with dosing based on body weight. The FDA granted Aqneursa multiple designations, including Priority Review and Orphan Drug status. Approval was awarded to IntraBio Inc.IntraBio Inc. #FDAApproval #NiemannPickDisease #RareDiseases #Neurology #Biotech #Aqneursa #OrphanDrug #Innovation